Celgene, incorporated in Delaware and headquartered in Summit, New Jersey, finds, develops and commercializes medicines for cancer and inflammatory ailments. It's a subsidiary of Bristol-Myers Squibb.

The company's major product is Revlimid (lenalidomide), in conjunction with dexamethasone for the treatment of multiple myeloma patients.

Revlimid is also approved in the USA for treating patients with transfusion-dependent anemia, because of Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Revlimid is marketed through proprietary risk-management supply programs, to ensure the safe and appropriate use of those pharmaceuticals. Vidaza is approved for the treatment of patients with MDS.